Authors:
Verdorfer, I
Brecevic, L
Saul, W
Schenker, B
Kirsch, M
Trautmann, U
Helm, G
Gramatzki, M
Gebhart, E
Citation: I. Verdorfer et al., Comparative genomic hybridization-aided unraveling of complex karyotypes in human hematopoietic neoplasias, CANC GENET, 124(1), 2001, pp. 1-6
Authors:
Stockmeyer, B
Elsasser, D
Dechant, M
Repp, R
Gramatzki, M
Glennie, MJ
van de Winkel, JGJ
Valerius, T
Citation: B. Stockmeyer et al., Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies, J IMMUNOL M, 248(1-2), 2001, pp. 103-111
Authors:
Honemann, D
Chatterjee, M
Savino, R
Bommert, K
Burger, R
Gramatzki, M
Dorken, B
Bargou, RC
Citation: D. Honemann et al., The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells, INT J CANC, 93(5), 2001, pp. 674-680
Authors:
Atzpodien, J
Kirchner, H
Illiger, HJ
Metzner, B
Ukena, D
Schott, H
Funke, PJ
Gramatzki, M
von Jurgensom, S
Wandert, T
Patzelt, T
Reitz, M
Citation: J. Atzpodien et al., IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastaticrenal cell carcinoma: long-term results of a controlled randomized clinical trial, BR J CANC, 85(8), 2001, pp. 1130-1136
Authors:
Wandt, H
Frank, M
Denzel, T
Aulitzky, W
Bodenstein, H
Brack, N
Duerk, H
Engberding, R
Fauser, A
Geer, T
Germann, B
Gramatzki, M
Kaesberger, J
Kisro, J
Knigge, O
Kochling, G
Kuse, R
Link, H
Neubauer, A
Ohl, S
Pfluger, R
Saal, J
Schakel, U
Schalk, K
Schmidt, H
Soucek, S
Wagner, T
Wilms, K
Winter, R
Ehninger, G
Citation: H. Wandt et al., The 10.000/mu l morning trigger for prophylactic platelet transfusion is safe: Prospective experience in 411 AML patients, HEMAT BLOOD, 40, 2001, pp. 488-490
Authors:
Feuring-Buske, M
Kneba, M
Unterhalt, M
Engert, A
Gramatzki, M
Hiller, E
Trumper, L
Brugger, W
Ostermann, H
Atzpodien, J
Hallek, M
Aulitzky, E
Hiddemann, W
Citation: M. Feuring-buske et al., IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, ANN HEMATOL, 79(9), 2000, pp. 493-500
Authors:
Stockmeyer, B
Dechant, M
van Egmond, M
Tutt, AL
Sundarapandiyan, K
Graziano, RF
Repp, R
Kalden, JR
Gramatzki, M
Glennie, MJ
van de Winkel, JGJ
Valerius, T
Citation: B. Stockmeyer et al., Triggering FC alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy, J IMMUNOL, 165(10), 2000, pp. 5954-5961
Authors:
Behr, TM
Wormann, B
Gramatzki, M
Riggert, J
Gratz, S
Behe, M
Griesinger, F
Sharkey, RM
Kolb, HJ
Hiddemann, W
Goldenberg, DM
Becker, W
Citation: Tm. Behr et al., Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, CLIN CANC R, 5(10), 1999, pp. 3304S-3314S
Authors:
Kniep, B
Schakel, K
Nimtz, M
Schwartz-Albiez, R
Schmitz, M
Northoff, H
Vilella, R
Gramatzki, M
Rieber, EP
Citation: B. Kniep et al., Differential expression of alpha 2-6 sialylated polylactosamine structuresby human B and T cells, GLYCOBIOLOG, 9(4), 1999, pp. 399-406
Authors:
Elsasser, D
Stadick, H
Stark, S
Van de Winkel, JGJ
Gramatzki, M
Schrott, KM
Valerius, T
Schafhauser, W
Citation: D. Elsasser et al., Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma, ANTICANC R, 19(2C), 1999, pp. 1525-1528
Authors:
Burger, R
Hansen-Hagge, TE
Drexler, HG
Gramatzki, M
Citation: R. Burger et al., Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: Suggestion for classification by immunophenotype and T-cell receptor studies, LEUK RES, 23(1), 1999, pp. 19-27
Authors:
Harrer, T
Schwab, J
Struff, WG
Schmitt, M
Ficker, JH
Rodl, W
Parsch, H
Kalden, JR
Gramatzki, M
Citation: T. Harrer et al., Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS, INFECTION, 26(6), 1998, pp. 368-374